Charity Registration Number 1121784 Company Registration Number 06249601 (England and Wales) JUNE HANCOCK MESOTHELIOMA RESEARCH FUND (COMPANY LIMITED BY GUARANTEE) TRUSTEES, REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2024 GHARITY GofiifyAlJSION FIRST CONTACT 06 JAN2 RECEIVED
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND CONTENTS Page Legal and administrative information Trustees. report Statement of trustees, responsibilities Independent Examinerfs Report Statement of financial activities Balan¢e sheet 10 Notes to the accounts 11-16
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND LEGAL AND ADMINISTRATIVE INFORMATION Trustees A Budgeo.. K Hill K Stubbs R Hancock D Small Secrelary A Budgen Charity number 1121784 Company number 06249601 Prlnciple address Riverside East 2 Millsands Sheffield S3 8DT Registered office RIVeide East 2 Millsands Sheffield S3 8DT Accountants Landin Wilcock & Co 68 Queen Street Sheffield SI 1WR Bankers CAF Bank 25 Kings Hill Avenue lQngs Hill West Malling Kent ME194TA HSBC 22, The Moor Sheffield S14PA
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND TRUSTEES. REPORT FOR THE YEAR ENDED 30 JUNE 2024 The trustees. who are also Ihe directors of the charity for the purposes of the Companies Act, submit their annual report and the unaudited financial statements of the June Hancock Mesothelioma Research Fund for the year ended 30 June 2024. Reference and adminislrattve infomiation set out on page 1 form part of this report. The "trustees confimi that th.ese financial statements comply with current slalut.ory requiremen.ts. in th.at they have complied with the Charities Act 2011. the Companies Act 2006, the Memorandum and Articles of Association and Accounting and Reporting by Charities= Statement of Recommended Practise applicable to chartties preparing their accounts in accordan wf(h the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019). Structure. governance and management The June Hancock Mesothelioma Research Fund is a registered charity {charity number 1121784) and a company limited by guarantee (company number 06249601). The charity's only voting members are its charity Irustees. It is currently managed by a committee of fNe who undertake all day lo day lasks associated wtlh running the charity and delivering its objedive5. No paid staff are employed. Goveming documents The charity was incorporated on 16th May 2007 and is govemed by its Memorandum and Artides of Assoaation. This report covers the accounting period for the year ended 30th June 2024. Recruitment of trustees The trustees meet regularly to discuss the chartty's progress and formulate general policy. They are ultimately responsible for the day-to-day management of the charity. including the making, enforcing and altering of rules, and the authority for all expenditure. Trustees are elected andlor re-elecled in accordance with the provisions set out in the organisation's constitution. The current operational management of the charity is conducted by the Trustees together with the help of several volunteers under the guidance of the trustees. All decisions of a management nature are rrode by the board of trnstees. the quotum is fity percent. The income and property of the charity shall be applied solely towards the promotion of its objects as set forth in the Memorandum of Association. No portion Ihereof shall be paid or transferred, directly or indirectly. by way of bonus or otherwise by way of profrt. to members of the charity. No member of the board of trustees shall be appointed to any office of the charity paid by way of salary or fees. Neither shall they receive any remuneration or other benefit in money or kind from the charity. The trustees, (who are also the direclors for the purposes of company law), who served during the year were: A Budgen K Hill K Stubbs R Hancock D Small None of tre trustees has any beneficial interest in the compary. All of the tTUStee5 are members of the company and guarantee to contribute £1 in the event of a winding up. New trustees are appointed by a resolution of the existing trustees, and there is no requirement for trustees to retire annually and seek re-appointment. New Irustees undertake an induction and training process that includes an inteNiew with the exisling trustees at which stage they are given a presenlation of the charity's objectives and activities. They will also be provided with a bible of documents that includes strategy information, financial accounts, truslee minutes. publicity materials, key project inf0mtIOn and Charity Commission information about the responsibilities of Charity Trustees.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 Rlsk assessment The trustees have assessed the maior risks to which the chaiity is exposed and are Satisfied that systems are in .p.lace to miti.9ate exposure to these risks. Tbe major risk to the charty is considered to be its reliance.on donations and fund raising from the general public. A significant reduction in income would limit the development of the charity and the achievement of its objecb'ves. Objectives and activities The objectives of the charity as described in tts Memorandum are- Promoting research into the prevention, treatment, alleviation and cJJre of mesothelioma and other asbestos related conditions- Disseminating infomiation about the said conditions (including bul not limiled lo. the results of research funded by the JHMRF) for the benefit of the public provided that the objecttves shall always be wholly and exclusively Charitable. The main policies undertaken through the financial year in furtherance of these objectives were.. Accepting donations from those Vlllshing to raise money specffically for research inlo mesolhelioma. People who have encountered the disease in themselves or loved ones can take comfort from the knowledge that the money raised will fund research to help sufferer5 of the disease now and in the future. Providing high qualty. easy to understsnd and up to date infortrration on E$othe110Ma in publications and on our website. This includes infomiation aboul the disease ttself. treatments, clinical trials, novel therapies, where to go for more help, and also detsils of regional asbestos support groups. Supporting events like Action Mesothelioma Oay to prowde infomation to patients and carers, promote a better understsnding of mesothelioma and raise awareness of the health implications of asbestos and asbestos products. Inviting applications for high quality mesothelioma research propcts in the UK. All applications are independently reviewed and assessed by a panel of experts. Public benefit We remain confident that we demonstrate properfy the public benefit expected by the Charity Commission in the way that our objectives slate above. The above objectives and activrties are dearfy of value to mesothelioma patients and their carers. famity and friends. The trustees confirm that they have complied wilh the requirements of Section 4 of the Charities Act 2011 to have due regard lo the public benefit guidance published by the Chartty Commission for England and Wales. Use of volunteers There are no volunteers used in the daily duties of the Charity, however. there are a number of academics and clinicians who volunteer lo assist with the peer review process for new grant and fellowship applications, and interirn and final reports submitted by existing grant holders.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 Grant award policy The JHMRF runs a competitive award process vA)en sufficient funds are available. Applications are invited in open, structured calls for high quality mesothelioma research projects. Health care professionals, post-do¢toral scientists and other suitably qualified applicant5 are invited to apply for awards. Work must be carried out at a -rèsearch" Instilution In Ihe UK". "Research projecls in basic science. translational fesearch "or applied -heallli are" considered but the primary focus must be mesotheliorna. The JHMRF funds major projects (up to £300,000), pumppriming grants (up to £25.000} and doctoral fellowships. A number of travel grants to attend scienlrfic conferences or training courses are also available up to a maximum of £500. All applications received by the deadline are peer-reviewed by at least three independent expert referees, in accordan with AMRC guidelines. Our network of contscts provides a source of volunteer peer reviewers with specific medical and Scientif expertise in a wide-range of areas. Applications and reviews are then scrutinised and prioritised by the JHMRF Scientific Advisory Group (SAG). The SAG comprises academics, research scientists and clinicians. It is currently chaired by a JHMRF trustee with research experience. ResearGh proposals are assessed against the following criterta: Quality of the research Importance of the research question(s) Relevance of the work lo JHMRF research stralegy Scienlffic potential of the research Originality of the research Ethicality and research governan of the research Sustainability of the research Management of the overall project Additionally, fellowship applications are assessed for quality and SUFtability of the candidate. the host institution and the supervisor. The review process generates a shortlist of prioritised applications, which is tsken, to the JHMRF Board of Trustees. The Board makes the final decision on funding after consideration of the SAG'S recommendations. Funding calls are advertised on the websites of organisations such as RD Info. The British Lung Foundation and Mesothelioma UK and circulated to the mesothelioma research community via the distribulion lists of special interest groups in the British Thoracic Oncology Group and the Bribsh Mesothelioma Interest Group. Achievements and performance Fund raising activities have not fully recovered post-pandemi¢ and this year the JHMRF has focused on consolidating funds in preparation for another funding round to open in 2025. While sponsored events and direct donations remain relativety low, the charity has been fortunate to receive a legacy and donations from our pather organisations raised at Action Mesothelioma Day (AMD) and other fund raising events held during the year. Due to increasing numbers of AMD events taking place in various locations across the county, the JHMRF trustees decided to continue the policy of raising awareness of the Fund by attending meetings organised by other groups. Trustees presented at AMD 2023 events run by patient support groups in Sheffield, Southamplon and Manchester. Principal Sources of Funding JHMRF'S principal source of funding is generous donations. mainly from people affected by the disease. It has not engaged in any fundraising acttvities in the current year to 30 June 2024.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 Achlevements and perfonnance continued The JHMRF relains its commilment to building research capacty in mesothelioma by offering travel grants to support. attendance at relevant training meetings and conferences. In 2024 the JHMRF awarded travel grants to three doctoral students from the Universities of Bradford. Liverpool and Sheffield Hallam to enable them to attend the 16th International Mesothelioma Interest Group (IMIGI 2023 conference held in the Lille Grand Palais, Lille, France. International conferences provide early career researchers with Ihe opportunity to present their own work and network with other researchers to leam about new developments in mesothelioma research. Their presentations included= 1. The role of Exportin-1 IXP01) within cisplatin resistsnt Malignant Pleural Mesothelioma and specifically the use of Selinexor IKPT-330) a seleclive inhibitor of nuclear export which is currenly used to treat haematological cancers" 2. A breathomics-based approach to improve malignant mesothelioma diagnosis., 3. Loss of BAP1 influences mesothelioma llUlar motilty suggesting new therapeutic approaches. Throughout the year, the JHMRF has conts'nued to work with extemal partners in the UK and Europe, including the European Lung Foundation. Asbestos Victim Support Groups and Mesothelioma Patient Support Groups. The JHMRF values these relationships to build a collaborative approach to mesothelioma research and drive improvements in treatment and care for patients. Financial revlew The Fund ha5 continued to receive some extremely generous donations throughout the year. Donations come mainly from people affected by the disease. The level and number of awards that will be offered in the future will e$sarilY be determined by the availability and sustainability of funding. Funds wll be set aside to support annual applications for pilot and feasibility studies, and for travel and educational awards. The next call for a major project award will be announced in due course. Reserves policy The current level of reserves stands at £278.667. It 15 the policy of the charity to mainlain unrestricted funds, which are the free reserves of the charity, the minimum level of reserves is £10,000. This provides sufficient funds to cover management, administration and support costs. Funds above this level will be available for the chartty lo support other projects in the future. Financial Instruments Objectives and policies The Charity's activities expose il to a number of financial risks including credtt risk and liquidity risk. The use of financial derivatives is govemed by the charty5 policies approved by the board of trustees, which provide written principles on the use of financial derivatives to manage these risks. The Charity does not use derivative financial instrLtments for speculative purposes.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND TRUSTEES, REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 Flnanclal Instruments - continued Credit Risk The Charty's principal-. financial assets are-bank"""balances and"" cash- ""tra"de and ' othér reIllab.Ies. and investments. The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by intemational credit-rating agencies. The Charity has no significant Cdit risk. Liquidity risk In order to maintain liquidity lo ensure that sufficient funds are available for ongoing operation5 and future developments, the Chartty uses a mixlure of long-tem and short-temi debt finance. Further details regarding liquidity risk can be found in the statement of accounting policies in the financial statements. Plans for the future The charity will continue to pursue rts main aim. which is to promote high qualty research into mesothelioma in the UK. The JHMRF will WO closety with the new Mesothelioma Research Network and other research partners to build collaborations and develop ideas that have potential to lead to 81 advances in research and care for mesothelioma. We will adopt a flexible approach to funding using small grants and training awards to support innovats.ve areas of research and major project awards to progress ideas further. The patient will remain at the heart of the JHMRF research strategy: mesothelioma is a disease with extremely poor outcomes and limited treatment oplions. Improwng care for people with me50thelioma and increasing the range of therapeutic options available to them is a priorTty area for the fund. We aim to achieve this by building a strong and well-balanced portfolio of reseah, the outputs from which will be of real benefit to palients. Mesothelioma is classed as an industrial disease and is caused by asbeslos exposure. The JHMRF will wort in partnership with other organisations like the HSE and the International Ban Asbestos Secretsriat to raise awareness of asbestos in order to reduce the risk of people contracting mesothelioma in the future. The JHMRF will continue to support the call for a worldwide ban on the mining and manulacture of asbestos products, and recognises the need to seek more sustainable methods of providing employment and shelter for vulnerable populations in developing countries. On behalf of the board of tnjstees Adrian Budgen Trustee Dated." 22 November 2024 Dan Small Trustee Dated: 22 November 2024
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 30 JUNE 2024 The trustees (who are also the directors of June Hancock Mesothelioma Research Fund for the purpose of company law} are responsible for preparing the financial statements in accordance with the Uniled Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations. Company law requires the trustees lo prepare financial statements for each financial year. Under company law the trustees must not approve the financial ststements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming reSoUrS and application of resour, including its income and expenditure. for the period. In preparing these accounts. the truslees are required to: select suitable accounting policies and apply them consistenty: observe the methods and principles in the Chartties SORP: make judgements and estimates that are reasonable and prudent- state whether applicable UK Accounting Standards have been followed, subject to any malerial departures disclosed and explained in the financial statements.. prepare accounts on the going concem basis unles5 tt is inappropriate to presume Ihat the company will continue in business. The Iruslees are responsible for keeping proper accounting records which disclose llth reasonable accuracy at any lime the financial position of the charitable company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularibes. Approved by the trustees of the Charity on 22 November 2024 and signed on its behalf by: Adrian Budgen Trustee Dan Small Truslee
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF JUNE HANCOCK MESOTHELIOMA RESEARCH FUND FOR THE YEAR ENDED 30 JUNE 2024 I report on the accounts ofthe Charity forthe year ended 30 June 2024 vthich are set out on pages 9 to 16. Your attention is to be drawn to the fact that the Charity has prepared the Financial Statements in accordance with the financial Reportlng Standard applicable in the UK and Republic of Ireland (FRS 102) in preferènce lu Ihe Accounling and Reporting by Charities.. Slalement of Recommended practi issued on 1 April 2005 which is referred to in the extant regulations but has since been withdrawn. l understand that this has been done in order for the accounts to provrde a true and fair view in accordance with the Generally Accepted Accounting Praclice effective for reporting periods beginning on or after 1 January 2019. Respective responsibilities of trustees and examlner The trustees (who are also the directors of the cornpany for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed. Having satisfied myself Ihat the charity is not subject lo audit under company law and is eligible for independent examination. il is my responsibility to.. examine the accounts under section 145 of the 2011 Act., to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5}(b) of the 2011 Act.. and to state whether parttcular matters have come to my attention. Basis of independent examlnerfs report My examination was canied out in accordance with the general Directions given by the Charity Commission. An examination includes a rewew of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees conceming any such matters. The procedures undertaken do not provide all the eviden that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view, and the report is limiied to those matters set out in the statement Independent examinerfs ststement In connection with my examination. no matter has come to ry attention.. (11 which gives me a reasonable cause to believe that in any material respect the requirements.. to keep accounting records in accordance with section 386 of Ihe Companies Act 2006= and to prepare accounts which accord with accounting records. comply with the accounting requirements of seclion 396 of the Companies Act 2006 and wth the methods and principles of the statement of Recommended Practice: Accounting and Reporting by Charities have not been met., or (21 to which. in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached. Tom Henshaw ACA Landin Wilcock & Co Chartered Accountants & Registered Auditors 68 Queen Street Sheffield S1 1WR
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 30 JUNE 2024 Unrestrf¢ted funds 2024 Total 2023 Total Notes Income and Endowments from: Income from Investments Income from donations and legacies 13,649 35,450 13,649 35,450 6,146 40,274 Total income and endowments 49.099 49.099 46,420 Ex enditure on: Charltable actlvity 1,908 1,908 5,496 Research Grants & Costs 1,259 1,259 597,580 Net galns on Investsments 11 15,028) (5,028) 1,052 Total resources expended (1,861) 604,128 Net incomel(expenditure) 50.960 50.960 (557,7081 Transfer5 beeen funds 10 Net movement in funds 50.960 50,960 {557,708) Total funds brought forward 227,707 227.707 785,415 Total funds carried forward 13 278.667 278,667 227.707 The results for the year derive from continuing activities and there were no income. resources expended or transfers with any Designated or Restricted Funds during the current or preceding financial period. The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND UNAUDITED BALANCE SHEET AS AT30 JUNE 2024 As reststed 2023 2024 Notes Current assets Investments Other debtors Cash at bank and in hand 11 183.164 1,105 345,434 173,814 882 569,730 529,703 744,426 Llabllitles Creditors.. amounts falling due within one year Research Grant5 12 1.260 178.189 1.032 215,911 (179,449) (216,943) Total assets less current liabilities 350.254 527,483 Creditors due after more than one year. Research Grants 171.587) (299,776) Net Assets 278.667 227.707 Income funds Unrestricted funds 278,667 227,707 Accumulated funds 13 278,667 227,707 The company is entitled to exemption from audrt under Section 477 Companies Act 2006 for the year ended 30 June 2024. The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Cofflpanies Act 2006. The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts. These accounts have been ppared in accordan with the provisions applicable to companies subject to the small companies, regime. The accounts were approved by the board on 22 November 2024 and were signed by.. Adrian Budgen Trustee Dan Small Trustee 10-
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2024 1 Accounting policles 1.1 Summary of significant accountlng policies and key accounting estlmates .'The principal accounling policies applied in the preparation of these financkql statements. aretset. out-. below. These policies have been consistendy applied to all the years presented, unless otherwise stated. 1.2 Statement of compliance The financial statements have been ppared in accordance th Accounting and Reporting by Charities.. Statement of Recommended Practi applicable to charities preparing their accounts in accordance with the Financial Reporttng Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - {Charrties SORP (FRS 102)). the Companies Act 2006 and the Charities Act 2011. 1.3 Basis of preparation June Hancock Mesolhelioma Research Fund meets Ihe definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or Iransaclion value unless otheiSe stated in the relevant accounting policy notes. The presentation and functional currency is considered to be pound5 Sterling because this is the urrency in the primary economic environment in which the Charity operates. The prior year comparatives have been reststed to reflect the following adjuslmenl: Fixed term cash deposits which mature over 6 months after the year end have been reclassified wtthin current asset inveslments. 1.4 Going concern The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concem nor any significant areas of uncertanty that affect the canying value of assets held by the charty. 1.5 Summary of disclosure exemptions The Charity has opted to adopt Bullelin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements. 1.6 Fund accounting policy Restricted funds are subject to specific conditions by donors as to how they may be used. Unrestricted funds comprise funds thal have been donated or generated through charitable activities which are not subject to any such usage conditions. Designated fund5 are those either set aside by the trustees for specific purposes, or funds which are treated as such in order to follow accounting trealment gurdelines as detailed within the Charities SORP IFRS 102) and the 2011 Charities Act. Further details of each fund are disdosed in note 13. 1.7 Incoming and endowments Donations, legacies and other fomis of voluntary income are recognised as incoming resources when there is entitlement, certainty of receipt. except insofar as they are incapable of financial measurement. Investment income Investment income is recognised on a re1vable basis.
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 1.8 Resources expended Resources expended are included in the Statement of Financial Aclivilies on an accruals basis, inclusive of any VAT which cannot be recovered. Expenditure which is dire¢tly attributable to charitable activities has been induded in this cost category. Govemance costs are those incJJrred in the management and operation of the chartty's projects and Charitable activities, together with any Cornplian cosls. 1.9 Taxation The Charity is considered to pass the test set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potenlially exempt from taxalion in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such incorne or gains are applied exclusively to charitable purpose5. 1.10 Cash and Cash Equivalents Cash and cash equivalents compllse cash on hand and call deposits, and other short-temi highly liquid investments that are readily converb'ble to a known amount of cash and are subject lo an insignificant risk of change in value. 1.11 Financial Instrurnents Classification.. Financial assets and financial liabilities are recognised when the charity becomes a paty to the contractual prowsions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities. Recognition and measurement: All financial assets and liabilities are inttialty measured at fair value, except for those financial assets classified as at fair value through income or expenditure, which are initially measured at fair value (which 45 normally the transaction price excluding transaction costs), unless the arrangements constitutes a financing transaction. If an arrangement constitutes a financing transaction. the financial asset or financial liability is measured at the present value of the future payntS discounted at a market rate of interest for a similar debt instrument. Financial assets and liabilities a only offset in the statement of financial position when, and only when there exists a legalty enforceable right to set off the recognised amounts and the Charity intends either to setue on a net basis. or to realise the asset and settle the liability simultaneously. Financial assets are derecognised when and only when a) the contractual rights lo the cash flows from the financial asset expire or are settled, b) the Charity transfers to another paty substantially all of the rtsks and rewards of ownership of the financial asset, or c) the Charity. despite having retsined some, but not all, snIficant risks and rewards of ownership, has transferred control of the asset to another party. Financial liabilities are derecognised onty vthen the obligation specified in the contract is discharged, cancelled or expires. 12-
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 2 Investment income UK bank interest receivable 13,649 6,146 3 Incomlng from donations and legacies 2024 2023 Donations receivable 35,450 40,274 4 Charitable actlvity costs 2024 2023 Fundraising and event expenditure 3,788 Governan costs 1,908 1,708 1,908 5,496 5 Govemance costs 2024 2023 Accountancy & Professional fees Bank charges mis11aneouS expenses 1.437 351 120 1,121 480 107 1,908 1,708 13-
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 6 Research Grants 2024,". YI**• 2023 Awarded in year. Projects and research fellowships Charge in SOFA Paid in the year Movemenl 1,259 1,259 (267.170) (265,911) 597,580 597,580 (97,189 500,391 Balance al start of year 515,687 15,296 Balance at end of year 249.776 515,687 Due within one year Due after more than one year 178.189 71,587 215,911 299.776 Balance at end of year 249.776 515,687 Grants awarded during the year. JHMRF awarded travel grants to three doctoral students from the Universitie5 of Bradford, Liverpool and Sheffield Hallam to enable them to attend the 16th Intemational Mesothelioma Interest Group (IMIG) 2023 Conferen held in the Lille Grand Palais. Lille, France. 7 Trustees No acting trustees (or any persons connected with them) received any remuneration during the year. No trustee travel expenses were reimbursed to Trustees during the year. (2023.. £Nil). 8 Employees Other than the trustees, the company had no employees. 9 Taxation The Charity is a registered tharity and is therefore exempt from taxation. 10 Transfers There was no income or resour$ expended by way of any Designated or Restricted Funds, hen there were no transfers between funds during the period. 14-
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 11 Investments As restated 2023 2024 Quoted Invéstments & Long Tèmi Deposits Balance al start of year 173,814 174,321 Additions in the year 4.321 545 Movement in valuation of investment 5,029 (1,0521 Balance at end of year 183,164 173,814 Investments includes an investment bond and two fvielve nK)nth deposit accounts. At 30 June 2024 the market value of the bond was £64,240 and the amounts held on deposit total £118,924. 12 Creditors.. amounts falling due within one year 2024 2023 Accruals 1,260 1,032 13 Analysis of net assets between funds Unrestrlcted funds 2024 Total 2023 Total Fund balances at 30 June 2023 are represented by.. Tangible fixed assets Current assets 529.703 529,703 744,426 Creditor5'. amounts falling due within one year (179.449) (179,H9) (216,943} Credilors.. amounts falling due after more than one year (71.587) (71,587) (299,7761 278.667 278,667 227,707 14 Contingent liabilities There were no contingent liabilities as at 30 June 2024. 15-
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2024 15 Capltsl comrnitments There were no capital commitments as at 30 June 2024. 16 Post balance sheet events There are no events after the balance sheet date which the trustees feel should be brought to the attention of the members. 17 Related Party Transactions There have been no related party transaclions in the reporting period that require disclosure.